COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland
Abstract Vaccination has been considered the most crucial defence against viral infections, including SARS-CoV-2. Numerous reports have demonstrated the effectiveness of the above vaccines in oncological patients. It has also been proven that, apart from vaccinations and oncological therapy, the cou...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-024-03895-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571690491576320 |
|---|---|
| author | Piotr Kosiorek Bożena Mikołuć Samuel Stróż Anna Hryniewicz Dorota E. Kazberuk Robert Milewski Anna Grzeszczuk Magdalena J. Borkowska Anna Stasiak‐Barmuta |
| author_facet | Piotr Kosiorek Bożena Mikołuć Samuel Stróż Anna Hryniewicz Dorota E. Kazberuk Robert Milewski Anna Grzeszczuk Magdalena J. Borkowska Anna Stasiak‐Barmuta |
| author_sort | Piotr Kosiorek |
| collection | DOAJ |
| description | Abstract Vaccination has been considered the most crucial defence against viral infections, including SARS-CoV-2. Numerous reports have demonstrated the effectiveness of the above vaccines in oncological patients. It has also been proven that, apart from vaccinations and oncological therapy, the course of the cancer process itself influences the magnitude of the humoral response, especially in people after infection with SARS-CoV-2. The phenomenon we observe seems to confirm the presence of a "natural" defence potential in a cancer patient's body, in this case, directed against infection with a viral pathogen. A "stronger" antiviral response also explains the asymptomatic course of SARS-CoV-2 infection in some of the above patients. To what extent the SARS-CoV-2 infection weakened the "natural" potential of the anticancer response in these patients remains an open question. Objective This study aimed to answer the question about the impact of the cancer process on the humoral response in oncological patients vaccinated against SARS-CoV-2 infection and in patients after COVID-19. Material and methods One thousand six hundred and sixty-eight people were observed. Over 2 years, 5,082 SARS-CoV-2 IgG and IgM antibody samples were determined. The concentration of antibodies was assessed in groups of oncological patients: those undergoing anticancer therapy after contracting COVID-19 and those after vaccination against the SARS-CoV-2 infection. Results The obtained results indicate a naturally more significant humoral response in oncological patients who have not been vaccinated and have not undergone anticancer therapy, such as radiotherapy, chemotherapy, or surgical intervention. The above observation applies to patients with breast, lung, colon, kidney, and testicular cancer, although the response varies significantly depending on the type of cancer. Graphical abstract |
| format | Article |
| id | doaj-art-eef5857df7e1483d86701aad0be481b3 |
| institution | Kabale University |
| issn | 1432-0851 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-eef5857df7e1483d86701aad0be481b32025-02-02T12:26:55ZengSpringerCancer Immunology, Immunotherapy1432-08512024-12-0174111310.1007/s00262-024-03895-zCOVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in PolandPiotr Kosiorek0Bożena Mikołuć1Samuel Stróż2Anna Hryniewicz3Dorota E. Kazberuk4Robert Milewski5Anna Grzeszczuk6Magdalena J. Borkowska7Anna Stasiak‐Barmuta8Department of Emergency, Maria Sklodowska‐Curie Bialystok Oncology CentreDepartment of Pediatrics, Rheumatology, Immunology and Metabolic Bone DiseasesDepartment of Clinical Immunology, Medical University of BiałystokDepartment of Rehabilitation, Medical University of BiałystokDepartment of Radiotherapy, Maria Sklodowska‐Curie Bialystok Oncology CentreDepartment of Biostatistics and Medical Informatics, Medical University of BiałystokDepartment of Infectious Diseases and Neuroinfection, Medical University of BiałystokDepartment of Radiotherapy, Maria Sklodowska‐Curie Bialystok Oncology CentreDepartment of Clinical Immunology, Medical University of BiałystokAbstract Vaccination has been considered the most crucial defence against viral infections, including SARS-CoV-2. Numerous reports have demonstrated the effectiveness of the above vaccines in oncological patients. It has also been proven that, apart from vaccinations and oncological therapy, the course of the cancer process itself influences the magnitude of the humoral response, especially in people after infection with SARS-CoV-2. The phenomenon we observe seems to confirm the presence of a "natural" defence potential in a cancer patient's body, in this case, directed against infection with a viral pathogen. A "stronger" antiviral response also explains the asymptomatic course of SARS-CoV-2 infection in some of the above patients. To what extent the SARS-CoV-2 infection weakened the "natural" potential of the anticancer response in these patients remains an open question. Objective This study aimed to answer the question about the impact of the cancer process on the humoral response in oncological patients vaccinated against SARS-CoV-2 infection and in patients after COVID-19. Material and methods One thousand six hundred and sixty-eight people were observed. Over 2 years, 5,082 SARS-CoV-2 IgG and IgM antibody samples were determined. The concentration of antibodies was assessed in groups of oncological patients: those undergoing anticancer therapy after contracting COVID-19 and those after vaccination against the SARS-CoV-2 infection. Results The obtained results indicate a naturally more significant humoral response in oncological patients who have not been vaccinated and have not undergone anticancer therapy, such as radiotherapy, chemotherapy, or surgical intervention. The above observation applies to patients with breast, lung, colon, kidney, and testicular cancer, although the response varies significantly depending on the type of cancer. Graphical abstracthttps://doi.org/10.1007/s00262-024-03895-zBreast cancerLung cancerColon cancerSARS-CoV-2COVID-19 |
| spellingShingle | Piotr Kosiorek Bożena Mikołuć Samuel Stróż Anna Hryniewicz Dorota E. Kazberuk Robert Milewski Anna Grzeszczuk Magdalena J. Borkowska Anna Stasiak‐Barmuta COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland Cancer Immunology, Immunotherapy Breast cancer Lung cancer Colon cancer SARS-CoV-2 COVID-19 |
| title | COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland |
| title_full | COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland |
| title_fullStr | COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland |
| title_full_unstemmed | COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland |
| title_short | COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland |
| title_sort | covid 19 sensitive tumour response 2 year assessment of the sars cov 2 humoral response in cancer patients in oncology hospital in poland |
| topic | Breast cancer Lung cancer Colon cancer SARS-CoV-2 COVID-19 |
| url | https://doi.org/10.1007/s00262-024-03895-z |
| work_keys_str_mv | AT piotrkosiorek covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT bozenamikołuc covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT samuelstroz covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT annahryniewicz covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT dorotaekazberuk covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT robertmilewski covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT annagrzeszczuk covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT magdalenajborkowska covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland AT annastasiakbarmuta covid19sensitivetumourresponse2yearassessmentofthesarscov2humoralresponseincancerpatientsinoncologyhospitalinpoland |